WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 ...
21hon MSN
Moderna's cancer vaccine is incredibly promising, but this could be a major obstacle to its success
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.
Moderna said its vaccine to protect against ebola was recommended to advance into a Phase 2/3 trial in Congo. Pending regulatory approval, Moderna's mRNA-1469 vaccine will be tested to prevent ...
Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.
Moderna released full data on its closely watched cancer vaccine developed with Merck.
Stéphane Bancel defended his melanoma data and argued that rivals can’t easily copy the technology.
April 24 (Reuters) - German biotech company CureVac sued Moderna in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac patents related to ...
Moderna (NasdaqGS:MRNA) and Merck reported detailed Phase 3 data for their individualized mRNA melanoma vaccine plus KEYTRUDA ...
The drop is a sharp reversal of a massive 2026 stock rally fueled by optimism over its personalized cancer vaccine.
The results, which triggered Moderna’s stock to drop, are “really encouraging,” says Karen Knudsen, CEO of the Parker ...
Moderna (NasdaqGS:MRNA) faces fresh regulatory questions as prediction markets start trading on FDA timelines for its ...
Moderna Inc. Chief Executive Officer Stephane Bancel said he believes the personalized mRNA cancer vaccine his company is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results